Abstracts Archive - Page 970 of 2425 - ACR Meeting Abstracts

Abstract Number: 235 • 2019 ACR/ARP Annual Meeting
Muscle Pressure Correlates with Pain Levels in Fibromyalgia Patients and Muscle Tension May Be the Cause of Their Pain
Alexandra Katz Small¹, Ben Small ², Josephine Anilao ², Jessica Polyak Wokurka ³ and Robert Katz ⁴, ¹Rush University Medical Center, Chicago, ²Rheumatology Associates, Chicago, IL, ³Rheumatology Associates, Chicago, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Previous research has found that muscle pressure as measured by a pressure gauge is three times higher in the trapezius muscle in fibromyalgia patients…
Abstract Number: 236 • 2019 ACR/ARP Annual Meeting
Repeat Muscle Pressures Measured in Fibromyalgia Patients and Compared with Pain Scores
Alexandra Katz Small¹, Ben Small ² and Robert Katz ³, ¹Rush University Medical Center, Chicago, ²Rheumatology Associates, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Patients meeting the ACR criteria for the diagnosis of fibromyalgia were evaluated for intramuscular pressure using a pressure gauge from a trained physician or…
Abstract Number: 237 • 2019 ACR/ARP Annual Meeting
Determination of Muscle Pressure in Patients with Fibromyalgia by Two Examiners; The Examiners Get Similar Results
Alexandra Katz Small¹, Ben Small ², Jessica Polyak Wokurka ² and Robert Katz ³, ¹Rush University Medical Center, Chicago, ²Rheumatology Associates, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Muscle pressure is increased in fibromyalgia as measured by a pressure gauge with a needle inserted into the trapezius muscle. We attempted to evaluate…
Abstract Number: 238 • 2019 ACR/ARP Annual Meeting
Muscle Pressure as Measured by a Manometer Correlates with Dolorimetry in Patients with Fibromyalgia
Alexandra Katz Small¹, Ben Small ², Jessica Polyak Wokurka ² and Robert Katz ³, ¹Rush University Medical Center, Chicago, ²Rheumatology Associates, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Muscle pressure is elevated in fibromyalgia patients compared to controls. We have demonstrated this finding in previous studies. We wanted to determine whether a…
Abstract Number: 239 • 2019 ACR/ARP Annual Meeting
The SELENA SLEDAI Is an Imperfect Measure of Lupus Disease Activity in Patients with Concomitant Fibromyalgia
Robert Katz¹, Jessica Polyak Wokurka ² and Ben Small ², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: The SELENA-SLEDAI is a tool for measuring the activity of systemic lupus. It is frequently used in clinical drug trials, but what is the…
Abstract Number: 240 • 2019 ACR/ARP Annual Meeting
Whom Do Patients with Fibromyalgia Turn to for Emotional Support?
Robert Katz¹, Jessica Polyak Wokurka ² and Ben Small ², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: Fibromyalgia patients often have intense symptoms, especially pain and fatigue. We asked them in an in-office questionnaire whom they turn to for emotional support.Methods:…
Abstract Number: 241 • 2019 ACR/ARP Annual Meeting
Comparing Patients with Fibromyalgia Syndrome with Non-Fibromyalgia Rheumatic Disease Patients Regarding Exercise
Robert Katz¹ and Jessica Polyak Wokurka ², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, Chicago
Background/Purpose: Exercise is reported to help patients with the fibromyalgia syndrome (FMS). We wanted to know whether FMS patients, compared to non-FMS rheumatic disease patients,…
Abstract Number: 242 • 2019 ACR/ARP Annual Meeting
The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Robert Katz¹, Jessica Polyak Wokurka ² and Ben Small ², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: To assess patients’ global assessment of frequently used treatments for the fibromyalgia syndrome (FMS), we asked patients with fibromyalgia to rank medications they have…
Abstract Number: 243 • 2019 ACR/ARP Annual Meeting
Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment
Robert Katz¹, Jessica Polyak Wokurka ² and Ben Small ², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: Some rheumatic disease patients have concomitant fibromyalgia. We wanted to determine treatment response in patients with and without concomitant fibromyalgia.Methods: Patients were diagnosed by…
Abstract Number: 244 • 2019 ACR/ARP Annual Meeting
Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Jennifer Lofland¹, Pamela Berry ², Feng Pan ², Chetan Karyekar ³, Hannah Guiang ⁴, Rebecca McTavish ⁴ and Melissa Thompson ⁴, ¹Janssen Scientific Affairs, LLC, Spring House, PA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Cornerstone Research Group, Inc, Burlington, ON, Canada
Background/Purpose: SLE is an autoimmune multi-system disease characterized by flares and more rarely remissions. Emerging biologic therapies for SLE are expected to change the treatment…
Abstract Number: 245 • 2019 ACR/ARP Annual Meeting
Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
Miao Jiang¹, Aimee Near ², Barnabas Desta ¹, Xia Wang ¹ and Edward Hammond ¹, ¹AstraZeneca, Gaithersburg, MD, ²IQVIA, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with high economic burden. This real-world study assessed health care resource utilization (HRU) and costs in a US…
Abstract Number: 246 • 2019 ACR/ARP Annual Meeting
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Nnenna Ezeh¹, Trevor McKown ¹, Shivani Garg ¹ and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients of color are more likely to have systemic lupus erythematosus (SLE) and a smoking history. Prior literature notes that both smoking and race…
Abstract Number: 247 • 2019 ACR/ARP Annual Meeting
Health Literacy, Adherence, and Quality of Life of Uveitis Patients
Claire Mueller ¹ and Ghazala O'Keefe¹, ¹Emory University School of Medicine, Atlanta, GA
Background/Purpose: To determine health literacy, medication adherence, and quality of life (QOL) of uveitis patients in order to understand how to deliver better and improved…
Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Caroline Swift ¹, Yvonne Viteri², Gail Bridges ³, Mary Dorholt ⁴ and Monal Kohli ⁵, ¹Express Scripts, St. Louis, MO, ²Accredo, Northvale, NJ, ³Accredo, Memphis, TN, ⁴Accredo, Maple Grove, MN, ⁵Express Scripts, Franklin Lakes, NJ
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…
Abstract Number: 249 • 2019 ACR/ARP Annual Meeting
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Damemarie Paul ¹, Xue Han², Irina Yermilov ³, Sarah Gibbs ³ and Michael Broder ³, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Abatacept is recommended as first-line biologic therapy in adult patients with moderate to severe RA. We aimed to assess real-world 1-year treatment persistence in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].